Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Duration of Rituximab Maintenance in FL

January 26th 2018

Long-Term Data With Copanlisib in Follicular Lymphoma

January 26th 2018

Follicular Lymphoma: Obinutuzumab and Chemotherapy

January 26th 2018

MAVORIC Trial in Cutaneous T-Cell Lymphoma

January 26th 2018

Primary Cutaneous T-cell Lymphoma: ALCANZA Trial

January 26th 2018

Role of Novel Therapies in Hodgkin Lymphoma

January 26th 2018

Novel Combinations in Relapsed Hodgkin Lymphoma

January 26th 2018

Hodgkin Lymphoma: Addressing the Elderly Population

January 26th 2018

Hodgkin Lymphoma: Important Findings from CheckMate 205

January 26th 2018

Hodgkin Lymphoma: Using Brentuximab Vedotin Frontline

January 26th 2018

ECHELON-1 Trial: Significance in Hodgkin Lymphoma

January 26th 2018

PET-Adapted Therapy Effective in Hodgkin Lymphoma

January 26th 2018

Investigators successfully used PET/CT scanning to determine whether patients with stage IIB to IVB Hodgkin lymphoma should switch from ABVD to BEACOPP.

FLT3 Inhibitors Continue to Move Through AML Pipeline

January 26th 2018

Catherine Smith, MD, discusses the evolution of FLT3 inhibition in AML and ongoing studies that are poised to potentially change practice.

Choosing New Agents for ITP

January 26th 2018

Investigating the Use of Fostamatinib in ITP

January 26th 2018

Novel Antibody Tested in First-Line DLBCL Therapy

January 25th 2018

Investigators are studying the value of polatuzumab vedotin in patients with intermediate- or high-risk diffuse large B-cell lymphoma.

Rituximab Biosimilar Succeeds in Phase III Follicular Lymphoma Trial

January 25th 2018

PF-05280586, a biosimilar for rituximab (Rituxan/MabThera), delivered positive top-line results in the phase III REFLECTIONS B3281006 follicular lymphoma trial.

Novel Agents Advance Field of AML

January 24th 2018

Gabriel Mannis, MD, discusses novel therapies shifting the treatment paradigm for patients with AML.

CHOP-RIT Superior for PFS Versus R-CHOP in High-Risk Follicular Lymphoma

January 23rd 2018

The CHOP-RIT regimen improved progression-free survival compared with R-CHOP alone in previously untreated patients with follicular lymphoma.

Dr. Smith on the Development of Active Therapeutic Combinations in Acute Myeloid Leukemia

January 23rd 2018

Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, discusses developing active therapeutic combinations for the treatment of patients with acute myeloid leukemia